# Overview

## Files

| File | Description |
|------|-------------|
| [01-overview.md](01-overview.md) | Executive summary and scope |
| [02-current-state.md](02-current-state.md) | Present-day conditions and data |
| [03-history.md](03-history.md) | Historical context and evolution |
| [04-root-causes.md](04-root-causes.md) | Systemic analysis of why problems exist |
| [05-stakeholders.md](05-stakeholders.md) | Who is affected and who has power |
| [06-opposition.md](06-opposition.md) | Who opposes reform and why |
| [07-solutions.md](07-solutions.md) | Proposed reforms and interventions |
| [08-roadmap.md](08-roadmap.md) | Implementation timeline and sequencing |
| [09-resources.md](09-resources.md) | Further reading and citations |
| [10-actions.md](10-actions.md) | What citizens can do |
| [11-legislation.md](11-legislation.md) | Draft legal text and model legislation |
| [12-perspectives.md](12-perspectives.md) | Political perspectives analysis with scoring and compromise proposals |

## Subtopics (20)

| Subtopic | Description |
|----------|-------------|
| [cannabis-legalization](cannabis-legalization/) | State legalization, federal scheduling, banking access, expungement |
| [opioid-crisis](opioid-crisis/) | Prescription opioids, fentanyl, overdose epidemic, Sackler accountability |
| [harm-reduction](harm-reduction/) | Needle exchange, safe injection sites, naloxone access, drug checking |
| [overdose-prevention](overdose-prevention/) | Naloxone distribution, Good Samaritan laws, fentanyl test strips |
| [drug-treatment](drug-treatment/) | Medication-assisted treatment, recovery services, treatment access |
| [drug-courts](drug-courts/) | Diversion programs, therapeutic courts, effectiveness evidence |
| [decriminalization](decriminalization/) | Portugal model, possession penalties, criminal vs health approach |
| [drug-scheduling](drug-scheduling/) | DEA classification, Schedule I reform, rescheduling process |
| [psychedelics](psychedelics/) | Psilocybin, MDMA therapy, research barriers, state initiatives |
| [racial-disparities](racial-disparities/) | Enforcement disparities, crack/powder sentencing, targeted policing |
| [drug-sentencing](drug-sentencing/) | Mandatory minimums, sentencing reform, federal vs state penalties |
| [prescription-drugs](prescription-drugs/) | Prescribing practices, PDMP systems, pill mills, doctor shopping |
| [drug-pricing](drug-pricing/) | Pharmaceutical costs, negotiation authority, generics, importation |
| [drug-trafficking](drug-trafficking/) | Cartels, border interdiction, dark web, supply-side enforcement |
| [international-drug-policy](international-drug-policy/) | War on drugs abroad, crop eradication, demand reduction, treaties |
| [youth-prevention](youth-prevention/) | School programs, DARE effectiveness, evidence-based prevention |
| [drug-testing](drug-testing/) | Workplace testing, welfare drug testing, student athlete testing |
| [alcohol-policy](alcohol-policy/) | Drinking age, DUI laws, advertising, treatment parity |
| [tobacco-nicotine](tobacco-nicotine/) | Vaping, FDA regulation, flavored products, smoking cessation |
| [pharmaceutical-industry](pharmaceutical-industry/) | Marketing practices, FDA approval, patent gaming, PBMs |

---

*[Back to Analysis Overview](../01-overview.md)*
